. Author manuscript; available in PMC: 2018 Sep 1.

Published in final edited form as: Clin Lab Med. 2017 Sep;37(3):527–546. doi: 10.1016/j.cll.2017.06.006

Table 2.

Mycosis Fungoides/Sezary Syndrome staging adapted per ISCL/EORTC revision[55]

Skin	T1		Limited patches, papules, plaques <10% body surface area^*
	T2		Patches, papules, plaques >10%^**
	T3		One or more tumors >1cm diameter
	T4		Confluent erythema >80% body surface area
Node	N0		No clinically abnormal peripheral lymph nodes; no biopsy required
	N1	N1a	Clinically abnormal peripheral lymph nodes biopsied: Dutch grade 1^*/NCI LN0-2; clone negative**
		N1b	Clinically abnormal peripheral lymph nodes biopsied: Dutch grade 1/NCI LN0-2; clone positive
	N2	N2a	Clinically abnormal peripheral lymph nodes biopsied: Dutch grade 2^**/NCI LN3; clone negative**
		N2b	Clinically abnormal peripheral lymph nodes biopsied: Dutch grade 2/NCI LN3; clone positive
	N3		Clinically abnormal peripheral lymph nodes biopsied: Dutch grade ¾ ^***/NCI LN4; clone positive or negative**
	Nx		Clinically abnormal peripheral lymph nodes, not biopsied
Visceral	M0		No visceral organ involvement
Visceral	M1		Visceral organ involvement (pathologically confirmed)^******
Blood	B0	B0a	Absent peripheral blood involvement (<5% Sezary cells); clone negative
		B0b	Absent peripheral blood involvement (<5% Sezary cells); clone positive
	B1	B1a	Low blood tumor burden >5% Sezary cells, but not B2; clone negative
		B1b	Low blood tumor burden >5% Sezary cells, but not B2; clone positive
	B2		High blood tumor burden, >1000 Sezary cells/ul^{^}; clone positive

may be divided into T1a patch or T1b patch/plaque;

^**

may be divided into T2a patch or T2b patch/plaque; ISCL International Society of Cutaneous Lymphoma; EORTC European Organization for the research and treatment of cancer;

^***

Dutch grade 1 includes dermatopathic lymphadenopathy;

^****

Dutch grade 2 includes early presence of cerebriform nuclei in aggregates;

^*****

Dutch grade 3, 4 are partial and complete effacement of lymph node architectures;

^******

spleen/liver may be considered involved by imaging;

^{^}

if Sezary cells cannot be measured, then expanded CD3+/CD4+ cells with CD4:CD8>10:1 or loss of CD7 or CD26 in the presence of T-cell clonality can be used for B2.

From Olsen, E., et al., Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood, 2007. 110(6): p. 1713–22; with permission.